PF-562271

• UNSPSC Description:

  PF-562271 (VS-6062) is a potent, ATP-competitive and reversible FAK and Pyk2 kinase inhibitor with IC50s of 1.5 nM and 13 nM, respectively[1].

• Target Antigen:

  FAK; Pyk2

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/PF-562271.html

• Purity:

  99.68

• Solubility:

  DMSO : 66.67 mg/mL (ultrasonic)

• Smiles:

  CS(=O)(N(C)C1=NC=CC=C1CNC2=NC(NC3=CC4=C(C=C3)NC(C4)=O)=NC=C2C(F)(F)F)=O

• Molecular Weight:

  507.49

• References & Citations:

  [1]Roberts WG, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res, 2008, 68(6), 1935-1944.|[2]Crompton BD, et al. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. Cancer Res. 2013 May 1;73(9):2873-83.|[3]Bagi CM, et al. Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases. Cancer. 2008 May 15;112(10):2313-21.Anticancer Drugs. 2023 Jul 14.|Breast Cancer Res. 2024 Mar 19;26(1):48.|Cancer Res. 2013 May 1;73(9):2873-83.|Carbohydr Polym. 2024 Feb 15, 326, 121637.|Cell Death Dis. 2022 Sep 10;13(9):783.|Cell Death Dis. 2023 Feb 24;14(2):157.|Cell Discov. 2022 Sep 6;8(1):84.|Cell Rep. 2023 Oct 5;42(10):113213.|Clin Cancer Res. 2019 Jul 15;25(14):4552-4566.|Environ Toxicol Pharmacol. 2023 Oct 20:104301.|Eur J Cell Biol. 2024 May 28;103(2):151427.|Harvard Medical School LINCS LIBRARY|Int J Cancer. 2015 Oct 1;137(7):1549-59.|J Nat Med. 2020 Sep;74(4):732-740.|Life Sci. 2021 Jan 25;119112.|Practical Oncology Journal. 2015, 29(5): 444-449.|Research Square Preprint. 2021 Dec.|Research Square Preprint. 2023 May 23.|Sci Rep. 2018 May 8;8(1):7228. |Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 1

• CAS Number:

  717907-75-0